Hosted on MSN1mon
Integra LifeSciences (NASDAQ:IART) Misses Q4 Revenue EstimatesIts non-GAAP profit of $0.97 per share was 13.5% above analysts’ consensus estimates. Is now the time to buy Integra LifeSciences? Find out by accessing our full research report, it’s free.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback